Details of the Drug Combinations

General Information of This Drug (ID: DM1237M)

• Drug Name: Alfacalcidol (DM1237M)
• Synonyms: Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572

Indication

Hyperparathyroidism; ICD 11: 5A51; Status: Approved [1]; Hypoparathyroidism; ICD 11: 5A50; Status: Approved [2]; Renal osteodystrophy; ICD 11: N.A.; Status: Approved [3]

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Alfacalcidol + Lumefantrine	DCZJYO1	Lumefantrine	DD2 (Cell Line: DD2)	[4]
Alfacalcidol + Lumefantrine	DCXDKND	Lumefantrine	Hepatoblastoma (Cell Line: HB3)	[4]
Alfacalcidol + Chloroquine	DC9ET3K	Chloroquine	Hepatoblastoma (Cell Line: HB3)	[4]
Alfacalcidol + Mefloquine	DCBA29L	Mefloquine	DD2 (Cell Line: DD2)	[4]

References

• [1] X-Linked Hypophosphatemia. 2012 Feb 9 [updated 2023 Dec 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(?) [Internet]. Seattle (WA): University of Washington, Seattle; 1993C2024.
• [2] Auditing the Efficacy and Safety of Alfacalcidol and Calcium Therapy in Idiopathic Hypoparathyroidism. J Clin Endocrinol Metab. 2019 Apr 1;104(4):1325-1335.
• [3] Cross-linked C-terminal telopeptide of type I collagen in serum before and after treatment with alfacalcidol and calcium carbonate in early and moderate chronic renal failure. Nephron. 2002 Oct;92(2):304-8.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.